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Objectives: The telemedicine is developing rapidly, but the integration of IT 
capabilities of e-Health in clinical practice is not so fast. Aim. To create an inte-
grated health information system for pediatrics according to results of research in 
e-Health. MethOds: 40 publications, 2 meta-analyses regarding the use of remote 
monitoring in healthcare from 2001 to 2014 y. were reviewed on the following top-
ics: • establishment of the remote collection of patient data; • automatic analysis 
of clinical data. Results: The studied systems were divided into 3 groups in terms 
of the integration of data mining in order to diagnose or predict exacerbations: • 
organizing the collection and analyzing of data with the module; • no organizing 
the collection, but implementing data analysis for a narrow range of diseases; • 
organizing the collection and analyzing of the data for realizing a narrow range of 
diseases. The evaluation of the proposed options for the transfer of data to their 
storage and analyses was conducted. Medical data system with integrated part of 
telemedicine is able to generate a huge stream of data, in which a simple analysis 
of the data on the local device aggregates (smartphone) can be used. For data 
storage organization is natural to use a relational database management system, 
and for the exchange of information - a standardized platform-independent pro-
tocols. cOnclusiOns: We propose the architecture of remote health monitoring 
and analytic system, in which in addition to the function of collecting patients 
data is a subsystem of patient monitoring, designed for an automatic assessment 
of the health indices and patient state. The study was supported by the Russian 
Foundation for Basic Research, the project ¹ 13-04-12055.
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Objectives: To examine an organization-wide strategy for improving continu-
ity of care across the hospital-community interface for older internal medicine 
patients, including: Automated predictive modeling, Reaching out to patients, 
and Monitoring. MethOds: The comprehensive strategy includes a data-driven 
high-risk patient identification algorithm, classifying all older Clalit enrollees (65+) 
according to their a-priori risk for readmission (scores range 0-100); a nurse–led 
intervention to target high risk patients in all general hospitals in Israel providing 
discharge planning intervention, coupled with a primary care clinic nurse reach-out 
intervention to assess post-discharge needs; and monitoring through standardized 
reports to all primary care clinics. We examined rate of visits with primary care 
provider within 3 days after discharge and rate of lack visits within 7 days after 
discharge. Results: We developed the Preadmission Readmission Detection Model 
(PREADM), a unique real-time admission risk identification algorithm, which exhib-
ited good predictive accuracy (c-stat = 0.69). On average 6,563 high-risk patients 
were targeted for in-hospital and primary care interventions each year. In 2012, 
the rate of primary care visits within 3 days after discharge was less than 50% and 
in 2013 and 2014 this rate increased to 62.1% and 66%, respectively. The rate of lack 
visits within 7 days after discharge also improved from 35% to 14% in 2012, 2013 
and 2014, respectively. cOnclusiOns: Feasibility of a large-scale organization-
wide strategy transitional care for high-risk older Clalit patients (in any hospital 
as well as in all community clinics) was established. Our results on improvement 
in early primary care follow-up after discharge indicate a significant improvement 
in continuity of care.
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Objectives: Readmission reduction is at the focus of health care systems 
worldwide in efforts to improve efficiency across care settings. Patients’ reports 
of their hospital to community transitional care experience are an important 
tool to detect breakdowns along the care continuum. We aimed to examine the 
relationship between patients’ reports on the experience of their transitional 
care process and the risk of readmissions. MethOds: A retrospective cohort 
study based on data of hospitalized members of Clalit, Israel’s largest inte-
grated health care provider and non-for-profit payer. Participants were aged 65 
and older, admitted to internal medicine departments between September 2012 
and February 2013. Readmission was defined as unplanned hospitalization to 
internal department or intensive care units within 30 days of discharge to any 
hospital. The Care Transition Measure (CTM) was used to evaluate patients’ tran-
sitional care experience. We examined differences in the rates of readmissions 
according to CTM scores, stratified according to a validated composite measure 
of known readmission risk factors (the Preadmission Readmission Prediction 
Model - PREADM). Results: A total of 2,626 patients completed the survey. The 
average CTM score was 85.7. Over 60% of respondents reported a good – excel-
lent transitional care experience (CTM above 80). Analysis of the difference in 
readmission rates within the high PREADM score group (10% highest score) by 
CTM score showed a 14% greater likelihood of readmission in those with medium-
low CTM scores (below 80) and those with high CTM scores (80 or higher) (22% 
and 25.5% readmission rate respectively). cOnclusiOns: This study shows 
that high-risk patients benefit from treatment focused on the patient and the 
experience of a good discharge, with a reduced risk of 14% in readmissions 
within 30 days. These findings support previous research on the importance of 
targeting patient-centered interventions to patients with the high readmission 
risk.
tics were done at cohort entry. Descriptive use of psychiatric healthcare care (medi-
cal visits, hospitalizations, psychoactive drug use (anticonvulsants, antipsychotics, 
antidepressants, anxiolytics, ADHD drugs, anticholinergics, lithium) was assessed 
during a 5-year follow-up period. Mean costs per patient was estimated at 1- and 
5-year period of follow-up. Bootstrap analyses were used to assess the differences 
in costs between 1-year and 5-year follow-up. Results: A total of 1,227 individuals 
were identifed (male: 80.3%; median age: 7 years). In the 1-year period after diagnosis, 
mean number of psychiatric medical visits was 7.5 ± 14.6 with mean cost per patient 
of $653CAD (95%CI: 582-723); those values reduced to 2.1 ± 4.2 and $205CAD(175-
235), respectively at 5-years. Psychiatric hospitalization rate was 10.4% with mean 
cost per patient $9,717CAD(7,253-12,180) at year 1; the rate and cost reduced to 3.7% 
and $4259 CAD(2,395-6,123) at 5-years. Psychoactive drug utilization was initially 
present in 49.3% of subjects, and increased to 53.2% at 5-years. Associated mean drug 
costs per patient increased from $622CAD(539-706) to $889CAD(786-991), in this time 
period. cOnclusiOns: While costs for psychiatric medical visits and hospitaliza-
tions decreased by more than half over 5 years, psychoactive drug costs rose by 43%. 
Access to long term care and monitoring among the ASD population is discussed.
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Objectives: To compare health resource utilization (HRU) among elderly patients 
exposed to drugs metabolized by a polymorphic drug metabolizing enzyme (DME) 
tested in a prospective registry for known drug-gene interaction risk (DGIR) vs. 
untested historical controls from Inovalon’s MORE2® database. MethOds: 
A retrospective cohort of historical controls age ≥ 65 years was identified with 
continuous enrollment, taking ≥ 3 prescription medications (July 1, 2012 - March 
31, 2013) and on ≥ 1 drugs metabolized by a polymorphic DME. Subjects were 
defined as having a first claim for ≥ 1 drug with genetic implications or a dose 
change on index. Demographic, clinical and economic variables, were collected 
via prospective registry on tested patients and propensity score matching was 
conducted (matching variables: age, gender, comorbidities, and baseline medica-
tions). Patients were stratified into potential and known DGIR groups via (Genelex 
Youscript®) software. Counts of HRU during 4 months follow-up post index-date 
included all-cause hospitalizations, emergency-room and clinic visits. Results: 
Interim analysis of 205 tested patients with a mean age of 75 ± 7 (58% female) 
were compared to 82,073 historical controls (mean age 74± 6, 61% female) using 
t-test (p< 0.0001). After matching 820 historical controls to the tested cohort, the 
standardized differences among the matching variables were less than 0.05. Over 
90% of the total cohort has DGIR. The counts of total HRU reported among tested 
patients was lower compared to historical cohort (2.10 vs 2.65, respectively). Any 
DGIR was associated with lower overall HRU counts among tested groups com-
pared to controls (p= 0.005). cOnclusiOns: Based on the interim analysis, we 
demonstrated the value of genetic testing of drug variation in an elderly popula-
tion. Higher HRU among elderly patients that were not tested may be linked to 
their DGIR. Routine genetic testing may result in lower HRU and their associated 
costs as well as improved patient care.
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Objectives: Product labeling conveys information about the potential risks of 
medication for healthcare professionals and consumers, but the consistency (or 
inconsistency) of such information is unknown. We sought to investigate the 
consistency of information intended for healthcare professionals versus con-
sumers about cardiovascular risks from stimulants approved in four English-
speaking countries. MethOds: Professional and consumer drug product labels 
were obtained in July 2014 from regulatory agencies in Australia, Canada, United 
Kingdom, and United States. Language describing the nature of the relationship 
between the drug and four major cardiovascular adverse events (elevated blood 
pressure and/or heart rate, stroke, myocardial infarction, and sudden death) was 
extracted verbatim and classified into one of four mutually exclusive categories: 
confirmed, unconfirmed, mixed and not mentioned. Results: We obtained pro-
fessional and consumer product labeling for 24 unique, approved stimulants (16 
US, 6 UK, 6 Canada, and 5 Australia). Language regarding the relationship between 
drug and cardiovascular adverse events was consistent for professional and con-
sumer audiences 54.5% of the time (59% US, 20% Australia, 58% Canada, 67% UK). 
One in three (32%) labels for professionals and consumers included inconsist-
ent language that described a drug-adverse event relationship as both confirmed 
and unconfirmed. cOnclusiOns: Regulator approved product labeling provides 
healthcare professionals and consumers with inconsistent messages regarding the 
certainty (or uncertainty) of the relationship between stimulant use and specific 
cardiovascular risks in children and adolescents. Professionals and consumers 
often receive “mixed” messages about the actual risk of a particular cardiovas-
cular event within the same label. The implications towards patient safety and 
outcomes warrants further study.
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